DOCSLIB.ORG

Systematic Molecular and Cytogenetic Screening of 100 Patients with Marfanoid Syndromes and Intellectual Disability P

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Systematic Molecular and Cytogenetic Screening of 100 Patients with Marfanoid Syndromes and Intellectual Disability P Systematic molecular and cytogenetic screening of 100 patients with marfanoid syndromes and intellectual disability P. Callier, B. Aral, N. Hanna, S. Lambert, H. Dindy, C. Ragon, M. Payet, Gwenaëlle Collod-Béroud, V. Carmignac, M. A. Delrue, et al. To cite this version: P. Callier, B. Aral, N. Hanna, S. Lambert, H. Dindy, et al.. Systematic molecular and cytogenetic screening of 100 patients with marfanoid syndromes and intellectual disability. Clinical Genetics, Wiley, 2013, 84 (6), pp.507–521. 10.1111/cge.12094. hal-01068032 HAL Id: hal-01068032 https://hal.archives-ouvertes.fr/hal-01068032 Submitted on 20 Dec 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. CLINICAL GENETICS doi: 10.1111/cge.12094 Original Article Systematic molecular and cytogenetic screening of 100 patients with marfanoid syndromes and intellectual disability Callier P, Aral B, Hanna N, Lambert S, Dindy H, Ragon C, Payet M, P Calliera,b,†,BAralb,c,†, Collod-Beroud G, Carmignac V, Delrue MA, Goizet C, Philip N, Busa T, N Hannad,†,SLambertb,c, Dulac Y, Missotte I, Sznajer Y, Toutain A, Francannet C, Megarbane A, H Dindyd, C Ragona,b, Julia S, Edouard T, Sarda P, Amiel J, Lyonnet S, Cormier-Daire V, Gilbert M Payeta,b, G Collod-Beroude, B, Jacquette A, Heron D, Collignon P, Lacombe D, Morice-Picard F, Jouk V Carmignacb,MADelruef, PS, Cusin V, Willems M, Sarrazin E, Amarof K, Coubes C, Addor MC, CGoizetf, N Philipg,TBusag, Journel H, Colin E, Khau Van Kien P, Baumann C, Leheup B, YDulach, I Missottei, Martin-Coignard D, Doco-Fenzy M, Goldenberg A, Plessis G, Thevenon J, Y Sznajerj, A Toutaink, Pasquier L, Odent S, Vabres P, Huet F, Marle N, Mosca-Boidron AL, C Francannetl,AMegarbanem, Mugneret F, Gauthier S, Binquet C, Thauvin-Robinet C, Jondeau G, n o p Boileau C, Faivre L. Systematic molecular and cytogenetic screening of S Julia , T Edouard ,PSarda , q q 100 patients with marfanoid syndromes and intellectual disability. JAmiel , S Lyonnet , Clin Genet 2013. © John Wiley & Sons A/S. Published by Blackwell V Cormier-Daireq, B Gilbertr, Publishing Ltd, 2013 A Jacquettes,DHerons, P Collignont, D Lacombef, The association of marfanoid habitus (MH) and intellectual disability (ID) F Morice-Picardf, PS Jouku, has been reported in the literature, with overlapping presentations and VCusinv, M Willemsq, genetic heterogeneity. A hundred patients (71 males and 29 females) with w w a MH and ID were recruited. Custom-designed 244K array-CGH E Sarrazin ,KAmarof , p x (Agilent®; Agilent Technologies Inc., Santa Clara, CA) and MED12, C Coubes , MC Addor , ZDHHC9, UPF3B, FBN1, TGFBR1 and TGFBR2 sequencing analyses H Journely, E Colinz,PKhau were performed. Eighty patients could be classified as isolated MH and Van Kienaa,CBaumannab, ID: 12 chromosomal imbalances, 1 FBN1 mutation and 1 possibly B Leheupac,DMartin- pathogenic MED12 mutation were found (17%). Twenty patients could be Coignardad, M Doco-Fenzyae, classified as ID with other extra-skeletal features of the Marfan syndrome A Goldenbergaf, G Plessisag, (MFS) spectrum: 4 pathogenic FBN1 mutations and 4 chromosomal J Thevenonah, L Pasquierai, imbalances were found (2 patients with both FBN1 mutation and S Odentai, P Vabresb,FHuetb, chromosomal rearrangement) (29%). These results suggest either that there NMarlea,b, AL Mosca- are more loci with genes yet to be discovered or that MH can also be a Boidrona,b, F Mugnereta, relatively non-specific feature of patients with ID. The search for aortic ah aj complications is mandatory even if MH is associated with ID since FBN1 SGauthier , C Binquet , b,ah mutations or rearrangements were found in some patients. The excess of C Thauvin-Robinet , males is in favour of the involvement of other X-linked genes. Although it G Jondeauv, C Boileaud was impossible to make a diagnosis in 80% of patients, these results will and L Faivreb,ah improve genetic counselling in families. aService de Cytogen´ etique,´ Plateau Conflictofinterest technique de Biologie, CHU, Dijon, France, bEquipe GAD, EA 4271, The authors declare no conflict of interest. Universite´ de Bourgogne, Dijon, France, cLaboratoire de Biologie Moleculaire,´ Plateau technique de Biologie, CHU, Dijon, France, dAPHP, Laboratoire de Biochimie et de Gen´ etique´ moleculaire,´ Hopitalˆ Ambroise Pare,´ Boulogne, France, eINSERM, UMR_S 910, Marseille, F-13000, France, fDepartement´ de Gen´ etique,´ CHU Bordeaux et Universite´ 1 de Bordeaux, Bordeaux, France, gDepartement´ de Gen´ etique,´ Assistance Publique Hopitauxˆ de Marseille, Marseille, France, hService de Cardiologie, CHU, Toulouse, France, iService de Pediatrie,´ Centre Hospitalier Territorial, Nouvelle Caledonie,´ France, jService de Gen´ etique,´ CHU, Louvain, Belgique, France, kService de Gen´ etique,´ CHU, Tours, France, lService de Gen´ etique,´ CHU, Clermont-Ferrand, France, mUnite´ de Gen´ etique´ Medicale,´ Facultede´ Medecine,´ Universite´ Saint Joseph, Beirut, Lebanon, nService de Gen´ etique,´ CHU, Toulouse, France, oService de Pediatrie,´ CHU, Toulouse, France, pService de Gen´ etique,´ CHU, Montpellier, France, qDepartement´ de Gen´ etique,´ Hopitalˆ Necker-Enfants Malades, Paris, France, rGen´ etique´ Medicale,´ CHU, Poitiers, France, sDepartement´ de Gen´ etique,´ Hopitalˆ PitieSalp´ etri´ ere,` Paris, France, tService de Gen´ etique´ Medicale,´ CH Font Pre,´ Toulon, France, uService de Gen´ etique´ Medicale,´ CHU, Grenoble, France, vCentre de Ref´ erence´ Maladie de Marfan, Hopitalˆ Bichat, Paris, France, wCentre de Ref´ erence´ Caraibeen des Maladies Rares Neurologiques et Neuromusculaires, CHU de Fort de France, Hopitalˆ Pierre Zobda-Quitman, La Martinique, France, xService de Gen´ etique´ Medicale,´ Centre Hospitalier Vaudois, Lausanne, Switzerland, yService de Gen´ etique´ Medicale,´ CH, Vannes, France, zDepartement´ de Gen´ etique,´ CHU, Angers, France, aaService de Biologie Moleculaire,´ CHU, Montpellier, France, abService de Gen´ etique´ Medicale,´ Hopitalˆ Robert Debre,´ Paris, France, acDepartement´ de Gen´ etique,´ CHU, Nancy, France, adService de gen´ etique´ Medicale,´ CH, Le Mans, France, aeDepartement´ de Gen´ etique´ et Centre de Ref´ erence´ Maladies Rares ‘Anomalies du Developpement´ et Syndromes Malformatifs’ de la region´ Est, CHU Reims et EA3801 SFR Cap-Sante,´ Reims, France, afDepartement´ de Gen´ etique,´ CHU, Rouen, France, agService de Gen´ etique,´ CHU, Caen, France, ahCentre de Gen´ etique´ et Centre de Ref´ erence´ Anomalies du Developpement´ et Syndromes Malformatifs, Hopitalˆ d’Enfants, Dijon, France, aiService de Gen´ etique´ Medicale´ et Centre de Ref´ erence´ Anomalies du Developpement´ de l’Ouest, CHU, Rennes, France, and ajCentre d’Investigation Clinique – Epidemiologie´ Clinique, CHU, Dijon, France †These authors equally contributed to the work. 2 Systematic molecular and cytogenetic screening Key words: FBN1 gene – intellectual disability – Lujan-Fryns – marfanoid syndromes – MED12 gene – submicroscopic chromosomal rearrangements Corresponding author: Laurence Faivre, MD, PhD, Centre de Gen´ etique,´ Hopitalˆ d’Enfants, 10 bd Marechal´ de Lattre de Tassigny, 21034 Dijon Cedex, France. Tel.: 00 33 380 293 300; fax: 00 33 380 293 266; e-mail: [email protected] Received 23 October 2012, revised and accepted for publication 4 January 2013 Marfan syndrome (MFS) is a multisystem genetic absent, but has been reported in two families, includ- disease that can affect the cardiovascular, skeletal, ing one patient who required aortic surgery (16, 17). In ophthalmic, and integumentary systems and the dura 2007, the systematic screening of 737 genes annotated mater. The diagnosis is based on an international in the Vertebrate Genome Annotation database on the classification (1–3). The severity of the condition lies human chromosome X in 250 families with syndromic in the risk of dilation and subsequent dissection of the or non-syndromic X-linked ID led to the identification ascending aorta. The FBN1 gene is the major gene of hemizygous mutations in the MED12 , ZDHHC9 , in patients with MFS, and variable expression of the and UPF3B genes in a very small number of familial disease has been largely identified within and between cases (18–20). The MED12 gene (MIM 300188, also families (4, 5). Patients with atypical presentations not called HOPA or TRAP230 ), located in Xq13, encodes fulfilling the criteria involving only one organ system for a subunit of the macromolecular complex known exist but are rare (6). Patients with MFS do not usually as Mediator, which is required for thyroid hormone- present with intellectual disability (ID) (7). Patients dependent activation and repression of transcription by with MFS can also display mutations in the TGFBR1 RNA polymerase II (21). Med12-deficient zebra fish and TGFBR2 genes (8). embryos show defects in the brain and neural crest The term marfanoid habitus (MH) is used to describe and do not survive beyond 1 week after fertilization patients with skeletal signs suggestive of MFS but (22). MED12 mutation have been found in only one who do not meet the international criteria (5, 7). The large
Load more

Recommended publications
  • Missense Mutations of MADH4: Characterization of the Mutational Hot Spot and Functional Consequences in Human Tumors
    Vol. 10, 1597–1604, March 1, 2004 Clinical Cancer Research 1597 Featured Article Missense Mutations of MADH4: Characterization of the Mutational Hot Spot and Functional Consequences in Human Tumors Christine A. Iacobuzio-Donahue,1 Jason Song,5 Introduction Giovanni Parmiagiani,4 Charles J. Yeo,2,3 Human pancreatic ductal adenocarcinomas inactivate the Ralph H. Hruban,1,2 and Scott E. Kern2 tumor suppressor gene MADH4 (DPC4, SMAD4) with a high frequency (1). This inactivation occurs most commonly by Departments of 1Pathology, 2Oncology, 3Surgery, and 4Public Health, The Johns Hopkins Medical Institutions, Baltimore, Maryland, and homozygous deletion (HD), but some tumors may also inacti- 5Temple University School of Medicine, Philadelphia, Pennsylvania vate the gene by loss of heterozygosity (LOH) coupled with a mutation in the remaining allele. Inactivation by nonsense mu- tation may cause the loss of protein expression by enhanced Abstract proteosomal degradation (2, 3). Even when expressed as protein, Purpose and Experimental Design: The mutational spec- missense mutations may result in loss of a specific function of trum of MADH4 (DPC4/SMAD4) opens valuable insights the Madh4 protein such as DNA binding or Smad protein into the functions of this protein that confer its tumor- interactions (2–9). Thus, the location of these mutations can suppressive nature in human tumors. We present the provide clues to key structural features that mediate the tumor- MADH4 genetic status determined on a new set of pancre- suppressive function of MADH4. atic, biliary, and duodenal cancers with comparison to the Members of the Smad protein family, including Madh4, mutational data reported for various tumor types.
    [Show full text]
  • New Microdeletion and Microduplication Syndromes: a Comprehensive Review
    Genetics and Molecular Biology, 37, 1 (suppl), 210-219 (2014) Copyright © 2014, Sociedade Brasileira de Genética. Printed in Brazil www.sbg.org.br Review Article New microdeletion and microduplication syndromes: A comprehensive review Julián Nevado1,2*, Rafaella Mergener3*, María Palomares-Bralo1,2, Karen Regina Souza3, Elena Vallespín1,2, Rocío Mena1,2, Víctor Martínez-Glez1,2, María Ángeles Mori1,2, Fernando Santos1,4, Sixto García-Miñaur1,4, Fé García-Santiago1,5, Elena Mansilla1,5, Luis Fernández1,6, María Luisa de Torres1,5, Mariluce Riegel3,7$ and Pablo Lapunzina1,4,8$ 1Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain. 2Section of Functional and Structural Genomics, Instituto de Genética Médica y Molecular, Hospital Universitario la Paz, Madrid, Spain. 3Programa de Pós-graduação em Genética e Biologia Molecular, Universidade Federal do Rio Grande do Sul, Porto Alegre,RS, Brazil. 4Section of Clinical Genetics, Instituto de Genética Médica y Molecular, Hospital Universitario la Paz, Madrid, Spain. 5Section of Cytogenetics, Instituto de Genética Médica y Molecular, Hospital Universitario la Paz, Madrid, Spain. 6Section of Preanalytics, Instituto de Genética Médica y Molecular, Hospital Universitario la Paz, Madrid, Spain. 7Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre, Porto Alegre ,RS, Brazil. 8Section of Molecular Endocrinology, Overgrowth Disordes Laboratory, Instituto de Genética Médica y Molecular, Hospital Universitario la Paz, Madrid, Spain. Abstract Several new microdeletion and microduplication syndromes are emerging as disorders that have been proven to cause multisystem pathologies frequently associated with intellectual disability (ID), multiple congenital anomalies (MCA), autistic spectrum disorders (ASD) and other phenotypic findings. In this paper, we review the “new” and emergent microdeletion and microduplication syndromes that have been described and recognized in recent years with the aim of summarizing their main characteristics and chromosomal regions involved.
    [Show full text]
  • Bio 102 Practice Problems Genetic Code and Mutation
    Bio 102 Practice Problems Genetic Code and Mutation Multiple choice: Unless otherwise directed, circle the one best answer: 1. Choose the one best answer: Beadle and Tatum mutagenized Neurospora to find strains that required arginine to live. Based on the classification of their mutants, they concluded that: A. one gene corresponds to one protein. B. DNA is the genetic material. C. "inborn errors of metabolism" were responsible for many diseases. D. DNA replication is semi-conservative. E. protein cannot be the genetic material. 2. Choose the one best answer. Which one of the following is NOT part of the definition of a gene? A. A physical unit of heredity B. Encodes a protein C. Segement of a chromosome D. Responsible for an inherited characteristic E. May be linked to other genes 3. A mutation converts an AGA codon to a TGA codon (in DNA). This mutation is a: A. Termination mutation B. Missense mutation C. Frameshift mutation D. Nonsense mutation E. Non-coding mutation 4. Beadle and Tatum performed a series of complex experiments that led to the idea that one gene encodes one enzyme. Which one of the following statements does not describe their experiments? A. They deduced the metabolic pathway for the synthesis of an amino acid. B. Many different auxotrophic mutants of Neurospora were isolated. C. Cells unable to make arginine cannot survive on minimal media. D. Some mutant cells could survive on minimal media if they were provided with citrulline or ornithine. E. Homogentisic acid accumulates and is excreted in the urine of diseased individuals. 5.
    [Show full text]
  • Megalencephaly and Macrocephaly
    277 Megalencephaly and Macrocephaly KellenD.Winden,MD,PhD1 Christopher J. Yuskaitis, MD, PhD1 Annapurna Poduri, MD, MPH2 1 Department of Neurology, Boston Children’s Hospital, Boston, Address for correspondence Annapurna Poduri, Epilepsy Genetics Massachusetts Program, Division of Epilepsy and Clinical Electrophysiology, 2 Epilepsy Genetics Program, Division of Epilepsy and Clinical Department of Neurology, Fegan 9, Boston Children’s Hospital, 300 Electrophysiology, Department of Neurology, Boston Children’s Longwood Avenue, Boston, MA 02115 Hospital, Boston, Massachusetts (e-mail: [email protected]). Semin Neurol 2015;35:277–287. Abstract Megalencephaly is a developmental disorder characterized by brain overgrowth secondary to increased size and/or numbers of neurons and glia. These disorders can be divided into metabolic and developmental categories based on their molecular etiologies. Metabolic megalencephalies are mostly caused by genetic defects in cellular metabolism, whereas developmental megalencephalies have recently been shown to be caused by alterations in signaling pathways that regulate neuronal replication, growth, and migration. These disorders often lead to epilepsy, developmental disabilities, and Keywords behavioral problems; specific disorders have associations with overgrowth or abnor- ► megalencephaly malities in other tissues. The molecular underpinnings of many of these disorders are ► hemimegalencephaly now understood, providing insight into how dysregulation of critical pathways leads to ►
    [Show full text]
  • Level Estimates of Maternal Smoking and Nicotine Replacement Therapy During Pregnancy
    Using primary care data to assess population- level estimates of maternal smoking and nicotine replacement therapy during pregnancy Nafeesa Nooruddin Dhalwani BSc MSc Thesis submitted to the University of Nottingham for the degree of Doctor of Philosophy November 2014 ABSTRACT Background: Smoking in pregnancy is the most significant preventable cause of poor health outcomes for women and their babies and, therefore, is a major public health concern. In the UK there is a wide range of interventions and support for pregnant women who want to quit. One of these is nicotine replacement therapy (NRT) which has been widely available for retail purchase and prescribing to pregnant women since 2005. However, measures of NRT prescribing in pregnant women are scarce. These measures are vital to assess its usefulness in smoking cessation during pregnancy at a population level. Furthermore, evidence of NRT safety in pregnancy for the mother and child’s health so far is nebulous, with existing studies being small or using retrospectively reported exposures. Aims and Objectives: The main aim of this work was to assess population- level estimates of maternal smoking and NRT prescribing in pregnancy and the safety of NRT for both the mother and the child in the UK. Currently, the only population-level data on UK maternal smoking are from repeated cross-sectional surveys or routinely collected maternity data during pregnancy or at delivery. These obtain information at one point in time, and there are no population-level data on NRT use available. As a novel approach, therefore, this thesis used the routinely collected primary care data that are currently available for approximately 6% of the UK population and provide longitudinal/prospectively recorded information throughout pregnancy.
    [Show full text]
  • Prenatal Diagnosis of Frequently Seen Fetal Syndromes (AZ)
    Prenatal diagnosis of frequently seen fetal syndromes (A-Z) Ibrahim Bildirici,MD Professor of OBGYN ACIBADEM University SOM Attending Perinatologist ACIBADEM MASLAK Hospital Amniotic band sequence: Amniotic band sequence refers to a highly variable spectrum of congenital anomalies that occur in association with amniotic bands The estimated incidence of ABS ranges from 1:1200 to 1:15,000 in live births, and 1:70 in stillbirths Anomalies include: Craniofacial abnormalities — eg, encephalocele, exencephaly, clefts, which are often in unusual locations; anencephaly. Body wall defects (especially if not in the midline), abdominal or thoracic contents may herniate through a body wall defect and into the amniotic cavity. Limb defects — constriction rings, amputation, syndactyly, clubfoot, hand deformities, lymphedema distal to a constriction ring. Visceral defects — eg, lung hypoplasia. Other — Autotransplanted tissue on skin tags, spinal defects, scoliosis, ambiguous genitalia, short umbilical cord due to restricted motion of the fetus Arthrogryposis •Multiple congenital joint contractures/ankyloses involving two or more body areas •Pena Shokeir phenotype micrognathia, multiple contractures, camptodactyly (persistent finger flexion), polyhydramnios *many are AR *Lethal due to pulmonary hypoplasia • Distal arthrogryposis Subset of non-progressive contractures w/o associated primary neurologic or muscle disease Beckwith Wiedemannn Syndrome Macrosomia Hemihyperplasia Macroglossia Ventral wall defects Predisposition to embryonal tumors Neonatal hypoglycemia Variable developmental delay 85% sporadic with normal karyotype 10-15% autosomal dominant inheritance 10-20% with paternal uniparental disomy (Both copies of 11p15 derived from father) ***Imprinting related disorder 1/13 000. Binder Phenotype a flat profile and depressed nasal bridge. Short nose, short columella, flat naso-labial angle and perialar flattening Isolated Binder Phenotype transmission would be autosomal dominant Binder Phenotype can also be an important sign of chondrodysplasia punctata (CDDP) 1.
    [Show full text]
  • Nonsense and Missense Mutations in Hemophilia A: Estimate of the Relative Mutation Rate at CG Dinucleotides Hagop Youssoufian,* Stylianos E
    Am. J. Hum. Genet. 42:718-725, 1988 Nonsense and Missense Mutations in Hemophilia A: Estimate of the Relative Mutation Rate at CG Dinucleotides Hagop Youssoufian,* Stylianos E. Antonarakis,* William Bell,t Anne M. Griffin,4 and Haig H. Kazazian, Jr.* *Genetics Unit, Department of Pediatrics, and tDivision of Hematology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore; and tDivision of Hematology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill Summary Hemophilia A is an X-linked disease of coagulation caused by deficiency of factor VIII. Using cloned cDNA and synthetic oligonucleotide probes, we have now screened 240 patients and found CG-to-TG transitions in an exon in nine. We have previously reported four of these patients; and here we report the remaining five, all of whom were severely affected. In one patient a TaqI site was lost in exon 23, and in the other four it was lost in exon 24. The novel exon 23 mutation is a CG-to-TG substitution at the codon for amino acid residue 2166, producing a nonsense codon in place of the normal codon for arginine. Simi- larly, the exon 24 mutations are also generated by CG-to-TG transitions, either on the sense strand produc- ing nonsense mutations or on the antisense strand producing missense mutations (Arg to Gln) at position 2228. The novel missense mutations are the first such mutations observed in association with severe hemo- philia A. These results provide further evidence that recurrent mutations are not uncommon in hemophilia A, and they also allow us to estimate that the extent of hypermutability of CG dinucleotides is 10-20 times greater than the average mutation rate for hemophilia A.
    [Show full text]
  • MED12 Mutations Link Intellectual Disability Syndromes with Dysregulated GLI3-Dependent Sonic Hedgehog Signaling
    MED12 mutations link intellectual disability syndromes with dysregulated GLI3-dependent Sonic Hedgehog signaling Haiying Zhoua, Jason M. Spaethb, Nam Hee Kimb, Xuan Xub, Michael J. Friezc, Charles E. Schwartzc, and Thomas G. Boyerb,1 aDepartment of Molecular and Cell Biology, Howard Hughes Medical Institute, University of California, Berkeley, CA 94270; bDepartment of Molecular Medicine, Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229; and cGreenwood Genetic Center, Greenwood, SC 29646 Edited by Robert G. Roeder, The Rockefeller University, New York, NY, and approved September 13, 2012 (received for review December 20, 2011) Recurrent missense mutations in the RNA polymerase II Mediator divergent “tail” and “kinase” modules through which most activa- subunit MED12 are associated with X-linked intellectual disability tors and repressors target Mediator. The kinase module, compris- (XLID) and multiple congenital anomalies, including craniofacial, ing MED12, MED13, CDK8, and cyclin C, has been ascribed both musculoskeletal, and behavioral defects in humans with FG (or activating and repressing functions and exists in variable association Opitz-Kaveggia) and Lujan syndromes. However, the molecular with Mediator, implying that its regulatory role is restricted to a mechanism(s) underlying these phenotypes is poorly understood. subset of RNA polymerase II transcribed genes. Here we report that MED12 mutations R961W and N1007S causing Within the Mediator kinase module, MED12 is a critical trans- FG and Lujan syndromes, respectively, disrupt a Mediator-imposed ducer of regulatory information conveyed by signal-activated transcription factors linked to diverse developmental pathways, constraint on GLI3-dependent Sonic Hedgehog (SHH) signaling. We including the EGF, Notch, Wnt, and Hedgehog pathways (10–12).
    [Show full text]
  • The Genomics Era: the Future of Genetics in Medicine - Glossary
    The Genomics Era: the Future of Genetics in Medicine - Glossary The glossary below provides a list of key terms used throughout the course. You do not need to read them all now; we’ll be linking back to the main glossary step wherever these terms appear, so you may refer back to this list if you are unsure of the terminology being used. Term Definition The process of matching reads back to their original Alignment position in the reference genome. An allele is one of a number of alternative forms of the same gene or genetic locus. We inherit one copy Allele of our genetic code from our mother and one copy of our genetic code from our father. Each copy is known as an allele. Microarray based genomic comparative hybridisation. This is a technique used to detect chromosome imbalances by comparing patient and control DNA and comparing differences between the two sets. It is Array CGH a useful technique for detecting small chromosome deletions and duplications which would not have been detected with more traditional karyotyping techniques. A unit of DNA. There are four bases which form the Base cross links (or rungs) of the DNA double helix: adenine (A), thymine (T), guanine (G) and cytosine (C). Capture see Target enrichment. The process by which a cell becomes specialized in Cell differentiation order to perform a specific function. Centromere The point at which the sister chromatids are joined. #1 FutureLearn A structure located in the nucleus all living cells, comprised of DNA bound around proteins called histones. The normal number of chromosomes in each Chromosome human cell nucleus is 46 and is composed of 22 pairs of autosomes and a pair of sex chromosomes which determine gender: males have an X and a Y chromosome whilst females have two X chromosomes.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0210567 A1 Bevec (43) Pub
    US 2010O2.10567A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0210567 A1 Bevec (43) Pub. Date: Aug. 19, 2010 (54) USE OF ATUFTSINASATHERAPEUTIC Publication Classification AGENT (51) Int. Cl. A638/07 (2006.01) (76) Inventor: Dorian Bevec, Germering (DE) C07K 5/103 (2006.01) A6IP35/00 (2006.01) Correspondence Address: A6IPL/I6 (2006.01) WINSTEAD PC A6IP3L/20 (2006.01) i. 2O1 US (52) U.S. Cl. ........................................... 514/18: 530/330 9 (US) (57) ABSTRACT (21) Appl. No.: 12/677,311 The present invention is directed to the use of the peptide compound Thr-Lys-Pro-Arg-OH as a therapeutic agent for (22) PCT Filed: Sep. 9, 2008 the prophylaxis and/or treatment of cancer, autoimmune dis eases, fibrotic diseases, inflammatory diseases, neurodegen (86). PCT No.: PCT/EP2008/007470 erative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the S371 (c)(1), present invention relates to pharmaceutical compositions (2), (4) Date: Mar. 10, 2010 preferably inform of a lyophilisate or liquid buffersolution or artificial mother milk formulation or mother milk substitute (30) Foreign Application Priority Data containing the peptide Thr-Lys-Pro-Arg-OH optionally together with at least one pharmaceutically acceptable car Sep. 11, 2007 (EP) .................................. O7017754.8 rier, cryoprotectant, lyoprotectant, excipient and/or diluent. US 2010/0210567 A1 Aug. 19, 2010 USE OF ATUFTSNASATHERAPEUTIC ment of Hepatitis BVirus infection, diseases caused by Hepa AGENT titis B Virus infection, acute hepatitis, chronic hepatitis, full minant liver failure, liver cirrhosis, cancer associated with Hepatitis B Virus infection. 0001. The present invention is directed to the use of the Cancer, Tumors, Proliferative Diseases, Malignancies and peptide compound Thr-Lys-Pro-Arg-OH (Tuftsin) as a thera their Metastases peutic agent for the prophylaxis and/or treatment of cancer, 0008.
    [Show full text]
  • 11 Selected Syndromes and Associations
    11 Selected Syndromes and Associations ĭ Apert Syndrome Definition: Also known as acrocephalic syndac- Other anomalies of the cardiac, renal, and tyly syndrome. It is characterized by a “tower- gastrointestinal systems may also be present. shaped” head, facial dysmorphism, and sym- metrical syndactyly of the fingers and toes. Ultrasound findings: The earliest prenatal diag- nosis was possible at 12 weeks of gestation with Incidence: about one in 100 000 births. nuchal translucency measurements. Syndactyly First described in 1906 by Apert. could also be detected at this stage. At a later stage, an unusual shape of the head resulting Etiology/genetics: Partly autosomal-dominant from premature closure of the cranial sutures inheritance, but frequently sporadic occurrence (tower-shaped head) and facial dysmorphism (new mutation). Advanced paternal age is a fac- (hypoplasia of the midfacial region) are charac- tor favoring its occurrence. Gene defect in the fi- teristic features. Detailed scanning may also re- broblast growth factor receptor-2 gene (FGFR2), veal deep-set ears, unusual shape of the nose, gene locus: 10q26. exophthalmos, and hypertelorism. Clinical features: “Tower-shaped” head, early Differential diagnosis: Carpenter syndrome, closure of cranial sutures, anomalies of the cervi- Crouzon syndrome, cloverleaf skull anomaly, cal vertebral column. Facial anomalies: denting Pfeiffer syndrome, thanatophoric dysplasia, of the forehead in the supraorbital region, hyper- achondrogenesis, Cornelia de Lange syndrome, telorism, flat orbital bone, exophthalmos, squint, EEC syndrome, Fryns syndrome, Joubert syn- deep-set ears, small, beak-shaped nose, syndac- drome, multiple pterygium syndrome, Noonan tyly (as extreme as “spoon hands”), fusion of the syndrome, Roberts syndrome, Smith–Lemli– bony parts of fingers II–IV, short fingers, possibly Opitz syndrome, trisomy 21.
    [Show full text]
  • VACTERL/VATER Association Benjamin D Solomon
    Solomon Orphanet Journal of Rare Diseases 2011, 6:56 http://www.ojrd.com/content/6/1/56 REVIEW Open Access VACTERL/VATER Association Benjamin D Solomon Abstract VACTERL/VATER association is typically defined by the presence of at least three of the following congenital malformations: vertebral defects, anal atresia, cardiac defects, tracheo-esophageal fistula, renal anomalies, and limb abnormalities. In addition to these core component features, patients may also have other congenital anomalies. Although diagnostic criteria vary, the incidence is estimated at approximately 1 in 10,000 to 1 in 40,000 live-born infants. The condition is ascertained clinically by the presence of the above-mentioned malformations; importantly, there should be no clinical or laboratory-based evidence for the presence of one of the many similar conditions, as the differential diagnosis is relatively large. This differential diagnosis includes (but is not limited to) Baller-Gerold syndrome, CHARGE syndrome, Currarino syndrome, deletion 22q11.2 syndrome, Fanconi anemia, Feingold syndrome, Fryns syndrome, MURCS association, oculo-auriculo-vertebral syndrome, Opitz G/BBB syndrome, Pallister- Hall syndrome, Townes-Brocks syndrome, and VACTERL with hydrocephalus. Though there are hints regarding causation, the aetiology has been identified only in a small fraction of patients to date, likely due to factors such as a high degree of clinical and causal heterogeneity, the largely sporadic nature of the disorder, and the presence of many similar conditions. New genetic research methods offer promise that the causes of VACTERL association will be better defined in the relatively near future. Antenatal diagnosis can be challenging, as certain component features can be difficult to ascertain prior to birth.
    [Show full text]